Francesca Bruzzese

2.4k total citations
55 papers, 1.7k citations indexed

About

Francesca Bruzzese is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Francesca Bruzzese has authored 55 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 30 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Francesca Bruzzese's work include Histone Deacetylase Inhibitors Research (20 papers), Peptidase Inhibition and Analysis (13 papers) and Chemotherapy-induced cardiotoxicity and mitigation (9 papers). Francesca Bruzzese is often cited by papers focused on Histone Deacetylase Inhibitors Research (20 papers), Peptidase Inhibition and Analysis (13 papers) and Chemotherapy-induced cardiotoxicity and mitigation (9 papers). Francesca Bruzzese collaborates with scholars based in Italy, United States and France. Francesca Bruzzese's co-authors include Alfredo Budillon, Elena Di Gennaro, Alessandra Leone, Michele Caraglia, Antonio Avallone, Maria Serena Roca, Monia Rocco, Biagio Pucci, Maria Rita Milone and Rita Lombardi and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Francesca Bruzzese

51 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francesca Bruzzese Italy 24 1.2k 593 308 293 131 55 1.7k
Quintin Pan United States 20 756 0.6× 739 1.2× 370 1.2× 261 0.9× 142 1.1× 40 1.8k
Chandra Prakash Prasad India 24 1.1k 1.0× 612 1.0× 359 1.2× 230 0.8× 73 0.6× 70 1.8k
Alessandra Leone Italy 22 934 0.8× 412 0.7× 312 1.0× 212 0.7× 96 0.7× 38 1.4k
Daqing Wu United States 24 942 0.8× 460 0.8× 279 0.9× 329 1.1× 104 0.8× 56 1.7k
Dongwei Zhang United States 16 589 0.5× 733 1.2× 281 0.9× 284 1.0× 187 1.4× 64 1.5k
Sheng-Chieh Hsu Taiwan 16 1.0k 0.9× 811 1.4× 364 1.2× 286 1.0× 65 0.5× 16 1.7k
Douglas C. Marchion United States 23 1.8k 1.5× 609 1.0× 253 0.8× 155 0.5× 93 0.7× 66 2.3k
Lijun Di China 25 1.0k 0.9× 602 1.0× 389 1.3× 188 0.6× 81 0.6× 102 1.9k
Jin Yang China 23 861 0.7× 606 1.0× 297 1.0× 228 0.8× 115 0.9× 87 1.5k
Shou‐Ching Tang United States 24 1.3k 1.1× 542 0.9× 504 1.6× 230 0.8× 70 0.5× 85 1.8k

Countries citing papers authored by Francesca Bruzzese

Since Specialization
Citations

This map shows the geographic impact of Francesca Bruzzese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Bruzzese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Bruzzese more than expected).

Fields of papers citing papers by Francesca Bruzzese

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Bruzzese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Bruzzese. The network helps show where Francesca Bruzzese may publish in the future.

Co-authorship network of co-authors of Francesca Bruzzese

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Bruzzese. A scholar is included among the top collaborators of Francesca Bruzzese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Bruzzese. Francesca Bruzzese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bua, Silvia, Alessio Nocentini, Alessandro Bonardi, et al.. (2024). Harnessing Nitric Oxide-Donating Benzofuroxans for Targeted Inhibition of Carbonic Anhydrase IX in Cancer. Journal of Medicinal Chemistry. 67(17). 15892–15907. 3 indexed citations
2.
3.
4.
5.
Vecchio, Vitale Del, Luigi Mele, Laura Mosca, et al.. (2023). β2-AR inhibition enhances EGFR antibody efficacy hampering the oxidative stress response machinery. Cell Death and Disease. 14(9). 613–613. 8 indexed citations
6.
Maurea, Nicola, Maria Laura Canale, Giuseppe Palma, et al.. (2023). SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity. European Heart Journal. 44(Supplement_2). 2 indexed citations
7.
Maurea, Nicola, Andrea Paccone, Flávia Martão Flório, et al.. (2023). SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study. European Heart Journal. 44(Supplement_2). 1 indexed citations
8.
Quagliariello, Vincenzo, Manuela Giovanna Basilicata, Giacomo Pepe, et al.. (2022). Combination of Spirulina platensis, Ganoderma lucidum and Moringa oleifera Improves Cardiac Functions and Reduces Pro-Inflammatory Biomarkers in Preclinical Models of Short-Term Doxorubicin-Mediated Cardiotoxicity: New Frontiers in Cardioncology?. Journal of Cardiovascular Development and Disease. 9(12). 423–423. 15 indexed citations
9.
Cocco, Stefania, Alessandra Leone, Maria Serena Roca, et al.. (2022). Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models. Journal of Translational Medicine. 20(1). 290–290. 79 indexed citations
10.
Das, Viswanath, Francesca Bruzzese, Petr Konečný, et al.. (2015). Pathophysiologically relevant in vitro tumor models for drug screening. Drug Discovery Today. 20(7). 848–855. 42 indexed citations
11.
Bizzarro, Valentina, Raffaella Belvedere, Maria Rita Milone, et al.. (2015). Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid. Oncotarget. 6(28). 25074–25092. 51 indexed citations
12.
Bruzzese, Francesca, Christina Hägglöf, Alessandra Leone, et al.. (2014). Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15. Cancer Research. 74(13). 3408–3417. 107 indexed citations
13.
Bruzzese, Francesca, Biagio Pucci, Maria Rita Milone, et al.. (2013). Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death and Disease. 4(10). e878–e878. 47 indexed citations
14.
Bruzzese, Francesca, Alessandra Leone, Monia Rocco, et al.. (2010). HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. Journal of Cellular Physiology. 226(9). 2378–2390. 119 indexed citations
15.
Gennaro, Elena Di, Geny Piro, Renato Franco, et al.. (2010). Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. British Journal of Cancer. 103(11). 1680–1691. 36 indexed citations
16.
Bruzzese, Francesca, Monia Rocco, Silvia Trini Castelli, et al.. (2009). Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Molecular Cancer Therapeutics. 8(11). 3075–3087. 90 indexed citations
17.
Budillon, Alfredo, et al.. (2006). Sequence-dependent synergistic antitumor interaction of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA, Vorinostat) in combination with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in non-small cell lung cancer cells. Cancer Research. 66. 574–574. 1 indexed citations
18.
Caraglia, Michele, Maurizio Marra, Carlo Leonetti, et al.. (2006). New strategies based on zoledronic acid/tipifarnib combination in the therapy of prostate cancer. Bone. 38(3). 44–44. 1 indexed citations
19.
Bruzzese, Francesca, Elena Di Gennaro, Antonio Avallone, et al.. (2006). Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-α in Head and Neck Cancer Cells In vitro and In vivo. Clinical Cancer Research. 12(2). 617–625. 76 indexed citations
20.
Gennaro, Elena Di, et al.. (2004). Acetylation of proteins as novel target for antitumor therapy: Review article. Amino Acids. 26(4). 435–41. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Quintin Pan Breakdown of academic impact, for papers by Chandra Prakash Prasad Breakdown of academic impact, for papers by Alessandra Leone Breakdown of academic impact, for papers by Daqing Wu Breakdown of academic impact, for papers by Dongwei Zhang Breakdown of academic impact, for papers by Sheng-Chieh Hsu Breakdown of academic impact, for papers by Douglas C. Marchion Breakdown of academic impact, for papers by Lijun Di Breakdown of academic impact, for papers by Jin Yang Breakdown of academic impact, for papers by Shou‐Ching Tang
Rankless by CCL
2026